Stocks TelegraphStocks Telegraph
Stock Ideas

XVIPF Company Profile and Key Details

PNK : XVIPF

Xvivo Perfusion AB (publ)

$42.76
-0.33-0.77%
At Close 4:00 PM

Price Chart

Stock Price Today

Xvivo Perfusion AB (publ) (XVIPF) stock remained unchanged at $29.48 a share on OTC. The stock opened at $29.48, fluctuating between $29.48 to $29.48 during the session.

Stock Snapshot

29.48
Prev. Close
928.6M
Market Cap
29.48
Day Low
147.27
P/E Ratio
0.20018
EPS (TTM)
0.1
Cash Flow per Share
29.48
Open
31.5M
Number of Shares
29.48
Day High
76.96%
Free Float in %
61.75
Book Value
100
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Jul 09, 202629.4829.4829.4829.48100
Jun 12, 202629.0029.0029.0029.00100
May 19, 202629.3929.3929.3929.39216
Mar 30, 202622.8122.8122.8122.81216
Mar 12, 202619.3319.3319.1519.15200
Mar 09, 202619.5419.7019.5419.70200
Feb 05, 202623.7923.7923.5223.52519
Feb 03, 202623.8523.8523.8523.85250
Feb 02, 202624.1524.1524.1524.15100
Jan 30, 202626.7526.7525.4925.49250
Jan 27, 202623.8024.7723.8024.77400
Jan 21, 202623.2523.2523.2523.25100
Jan 20, 202623.4323.4323.4323.43425
Jan 16, 202623.0523.0523.0523.05100
Jan 07, 202620.2720.2720.2720.27250
Dec 29, 202520.7020.7020.7020.70500
Dec 22, 202520.1120.1120.1120.11190
Dec 11, 202519.4019.4019.4019.40319
Dec 08, 202519.6419.6419.6419.641K
Dec 04, 202518.6018.6018.6018.60200

Contact Details

About Company

Xvivo Perfusion AB (publ) is a medical technology company dedicated to advancing transplantation medicine. The firm specializes in pioneering solutions for the preservation and perfusion of organs, tissues, and cells, essential for successful transplant procedures. With a significant international presence, Xvivo Perfusion operates across diverse markets, including Sweden, the United States, wider North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Among its key product offerings is the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass apparatus designed for normothermic ex vivo lung perfusion (EVLP). Complementing this, the company provides the XPS Disposable Lung Kit, comprising sterile, pre-packaged components required for EVLP, and STEEN Solution, a specialized buffered extracellular fluid used for perfusing isolated donor lungs during the EVLP process. Xvivo also offers Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte solution crucial for preservation. Other significant products include the XVIVO Silicone Tubing Set for rapid flushing of donor lungs post-procurement; the XVIVO LS and XVIVO Disposable Lung Set, devices engineered for EVLP; and the XVIVO Organ Chamber, a single-use sterile container designed for the temporary storage of isolated lungs prior to their transplantation into a recipient. Additionally, the XVIVO Lung Cannula Set, a sterile, single-use disposable product, is part of their portfolio. Established in 1998, Xvivo Perfusion AB (publ) maintains its headquarters in Gothenburg, Sweden.

Company Information

Employees193
Beta1.46
Sales or Revenue$822.42M
5Y Sales Change%1.795%
Fiscal Year EndsDecember
SectorHealthcare
IndustryMedical - Devices

Company Overview

The stock is currently trading near its 52-week high $16.98 and $29.48. With a market capitalization of about $928.60 million, Xvivo Perfusion AB (publ) is classified as a small-cap and shows higher-than-market volatility (beta ~1.46). Key stats such as the average daily volume over the past year has been around 6.00 shares, trading with heavier-than-usual volume. Headquartered in Gothenburg, None, Xvivo Perfusion AB (publ) operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Christoffer Rosenblad, the company employs approximately 199 people and listed since July 21, 2014. Xvivo Perfusion AB (publ) is a medical technology company dedicated to advancing transplantation medicine.

Technical Performance

Average 10-day trading volume of 100.00 shares is below the 3-month average of 138.67, indicating normal recent market interest.

Valuation Metrics

Xvivo Perfusion AB (publ) trades at a P/E ratio of 122.37, slightly above the S&P 500 average, with a price-to-sales ratio of 10.83 and a price-to-book ratio of 4.16 trading at moderately above to book value. The P/FCF stands at 59.86, also above market averages.

Dividend & Fair Value

Xvivo Perfusion AB (publ) last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$14.94. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Xvivo Perfusion AB (publ) earnings surprise history is a mixed track record. The quarter that ended April 24, 2026, missed forecasts by 24.48%. The prior quarter beat by 52.82%. Over the last six quarters, Apple has recorded several small beats. These include -16.93% in January 28, 2025.

Financial & Profitability Overview

Over the trailing twelve months, Xvivo Perfusion AB (publ) generated $822.42M in revenue, or $25.96 per share. Gross margin was 74.95%, operating margin 10.74%, and net profit margin 20.94%. Returns are modest, with ROA at 7.84% and ROE at 8.85%.
On valuation metrics, Xvivo Perfusion AB (publ) trades at a P/E of 122.37, P/S of 10.83 and P/B of 4.16. The current ratio is 4.52 and quick ratio is 3.10. Operationally, the company’s inventory turnover is 1.14 and cash conversion cycle is 194.39 days. Debt-to-equity is 0.06, supported by a cash flow-to-debt ratio of 1.48.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2024, Xvivo Perfusion AB (publ) posted revenue of $822.42M, down slightly from $597.54M in the prior quarter. Gross profit was $616.42M (margin 74.95%). Operating income was $88.35M (margin 10.7%). Net income was$172.18M (EPS $5.47).
The company ended the quarter with $546.09M in cash and short-term investments, a total debt of $31.44M, and net debt of - $214.65M. Total assets were $2.20B, with equity of $1.95B. Financials further reflected stability, with operating cash flow of $46.29M, free cash flow of - $97.65M, and capital expenditures of - $143.94M.

Price Forecast & Outlook

Our AI price prediction model suggests that Xvivo Perfusion AB (publ) stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows Xvivo Perfusion AB (publ) trading at a premium to the broader market with a P/E of 122.37.

Frequently Asked Questions

What is the current Xvivo Perfusion AB (publ) (XVIPF) stock price?
Xvivo Perfusion AB (publ) (OTC: XVIPF) stock price is $29.48 in the last trading session. During the trading session, XVIPF stock reached the peak price of $29.48 while $29.48 was the lowest point it dropped to. The percentage change in XVIPF stock occurred in the recent session was 0% while the dollar amount for the price change in XVIPF stock was $0.00.
XVIPF's industry and sector of operation?
The OTC listed XVIPF is part of Medical - Devices industry that operates in the broader Healthcare sector. Xvivo Perfusion AB (publ) designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of XVIPF?
Ms. Charlotte Walldal
Global R&D director
Mr. Johan Holmstrom
Chief Commercial Officer
Ms. Katrin Gisselfalt Ph.D.
Global Quality Assurance & Regulatory Affairs Director
Mr. Christer de Flon
Mang.
Mr. Christoffer Rosenblad
Chief Executive Officer
Jaya Tiwari
Vice President Clinical and Regulatory Affairs
Mr. Kristoffer Nordstrom
Chief Financial Officer & Investor Relations
Ms. Lena Hagman B.Sc.
Chief Operating Officer
Dr. Magnus Nilsson Ph.D.
Senior Advisor
Mr. Andreas Wallinder M.D., Ph.D.
Chief Medical Officer
How XVIPF did perform over past 52-week?
XVIPF's closing price is 114.87% higher than its 52-week low of $16.98 where as its distance from 52-week high of $29.48 is -0.81%.
How many employees does XVIPF have?
Number of XVIPF employees currently stands at 193.
Link for XVIPF official website?
Official Website of XVIPF is: https://www.xvivoperfusion.com
How do I contact XVIPF?
XVIPF could be contacted at phone 463 178 82150 and can also be accessed through its website. XVIPF operates from MAessans gata 10, Gothenburg, 412 51, Sweden.
How many shares of XVIPF are traded daily?
XVIPF stock volume for the day was 100 shares. The average number of XVIPF shares traded daily for last 3 months was 6.
What is the market cap of XVIPF currently?
The market value of XVIPF currently stands at $928.60M with its latest stock price at $29.48 and 31.5M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph